Journal of Pediatric Hematology/Oncology · 2008 · 33 citations · 9 references
MedicineNeurologyOncologyChemotherapyNeuromuscular DisordersNeurotoxicologyCharcot-marie-tooth DiseaseClinical NeurotoxicologyMotor NeuropathyNerve Conduction StudiesNeurotoxic InjuryPeripheral Nervous System ToxicityAcute Lymphoblastic Leukemia TreatmentClinical RemissionDisease Remission InductionElectrophysiologic EffectsGaitPeripheral Nerve Conduction DeficitsRemission Induction TherapySensory-motor Neuropathy
SUMMARY: We report a 13-year-old male patient with Charcot-Marie-Tooth disease (CMT) type 2 who developed severe neuropathy because of vincristine (VCR) for his acute lymphoblastic leukemia. A clumsy gait, muscle weakness in his fingers, and inverted champagne bottlelike muscle in the lower limbs were noticed after remission induction treatment for acute lymphoblastic leukemia, which included VCR at a total dose of 8 mg/m. An electrophysiologic study showed an almost normal median motor nerve conduction velocity (approximately 50 m/s), markedly reduced M-wave amplitude and sensory disturbance. He was diagnosed as CMT type 2 based on his symptoms and electrophysiologic findings. His symptoms gradually worsened, and even after VCR was discontinued, he could not walk alone for 7 months. VCR has previously been considered to be relatively safe in CMT type 2, however, some patients with CMT type 2 might show severe neurologic toxicities, as seen in patients with CMT type 1.
9
Severe vincristine neuropathy in charcot‐marie‐tooth disease type 1A
W. Graf, Phillip F. Chance, M. William Lensch et al. · Cancer · 1996 · 133 citations
Textbook of Pediatrics. 9th ed
Joyce D. Brink · Physical Therapy · 1970 · 93 citations